IVACTA Biotechnology's GT801 In Vivo CAR-T Shows 100% ORR and 75% CR Rate in NHL Patients at ASCO 2026
Jun 08, 2026 08:00
CST Updated
09:53
Vivacta
Cell Therapy Researcher
Grit Biotherapeutics
Developer of Immunotherapy Drugs for Solid Tumors